ISN Webinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials)

REGISTRATION

ISN Webinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials)

diabetes cardiac outcomes webinar

Kidney failure and cardiovascular complications are critical complications in diabetic patients. Further, kidney disease is a significant risk for cardiovascular events independently of classical risk factors, which is called cardiorenal connection.  Recent large-scale cardiovascular outcome studies such as EMPA-REG, CANVAS, and DELCARE TIMI 58, showed significant reduction in cardiovascular events. These studies recruited mainly patients without kidney disease but also included some patients with kidney disease. Analysis of the secondary endpoints of these studies demonstrated significant renoprotection.  Protective effects by SGLT2 inhibitor on the heart was confirmed by EMPA-REDUCED and DAPA-HF. This webinar will summarize the updated findings of clinical studies about cardiovascular outcome studies of SGLT2 inhibitor from a nephrologist point of view.

Learning objectives:

1. Obtain updated knowledge of cardiovascular outcome studies of SGLT2 inhibitor
2. Understand mechanisms of protective effects on the heart and the kidney by SGLT2 inhibitor
3. Understand potential benefits and harms of SGLT2 inhibitor based on cardiovascular outcome studies of SGLT2 inhibitor

Further reading:

Wanner C, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34.

Neal B, et al; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657

Wiviott SD, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357

Packer M, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424.

McMurray JJV, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.

ISN Webinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials)

24/2/20217:00am CET1 hour

Convert to my timezone